Erratum to "Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive" [Contraception 2009;80:445-51] (DOI:10.1016/j.contraception.2009.03.013);Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive

Contraception

Volumn 80, Issue 5, 2009, Pages 445-451

  Anttila, Leena ^a   Kunz, Michael ^b   Marr, Joachim ^b  

^a Family Federation of Finland   (Finland)

^b BAYER PHARMA AG   (Germany)

Author keywords

Bleeding pattern; combined oral contraceptive; cycle control; drospirenone; Pearl Index

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL;

ACNE; ADULT; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; MASTALGIA; MENSTRUAL CYCLE; METRORRHAGIA; MOOD CHANGE; NAUSEA; NORMAL HUMAN; ORAL CONTRACEPTION; PATIENT COMPLIANCE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SIDE EFFECT; TREATMENT DURATION;

EID: 70349773193     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.12.017     Document Type: Erratum

References (24)

1. Trussell J. Contraceptive efficacy. In: Hatcher R.A., Trussell J., Nelson A.L., Cates W., Stewart F.H., and Kowal D. (Eds). Contraceptive technology: nineteenth revised edition (2007), Ardent Media, New York 747-826
2. Shvarts S., Besinque K., Atkinson R., et al. New advances in contraception. Insights (2002) 11-22
3. Rosenberg M.J., and Waugh M.S. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 179 3 Pt 1 (1998) 577-582
4. Hatcher R.A., and Guillebaud J. The pill: combined oral contraceptives. In: Hatcher R.A., Trussell J., and Stewart F. (Eds). Contraceptive technology, seventeenth revised edition (1998), Ardent Media Inc, New York 405-466
5. Rosenberg M.J., and Long S.C. Oral contraceptives and cycle control: a critical review of the literature. Adv Contracept 8 suppl 1 (1992) 35-45
6. Kulier R., Helmerhorst F.M., Maitra N., and Gulmezoglu A.M. Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review. Reprod Health 1 (2004) 1-9
7. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62 (2000) 29-30
8. Bachmann G., Sulak P.J., Sampson-Landers C., et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 70 (2004) 191-198
9. Pearlstein T.B., Bachmann G.A., Zacur H.A., et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72 (2005) 414-421
10. Yonkers K.A., Brown C., Pearlstein T.B., et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106 (2005) 492-501
11. Maloney J.M., Dietz P., Watson D., et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 112 (2008) 773-781
12. Maloney J.M., Kunz M., Lee-Rugh S., et al. Drospirenone 3 mg/ethinylestradiol 20 μg COC in the treatment of acne vulgaris: investigator and subject self-assessment. Presented at ACOG: 5th-9th May 2007, San Diego, CA, Convention Center (2007)
13. Koltun W., Lucky A.W., Thiboutot D., et al. Efficacy and safety of 3 mg drospirenone /20 μg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 77 (2008) 249-256
14. Lucky A.W., Koltun W., Thiboutot D., et al. A combined oral contraceptive containing 3-mg drospirenone/20-μg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis 82 (2008) 143-150
15. Lammers P., and op ten Berg M. Phase III clinical trial with a new oral contraceptive containing 150 micrograms desogestrel and 20 micrograms ethinylestradiol. Acta Obstet Gynecol Scand 70 (1991) 497-500
16. Kirkman R.J., Pedersen J.H., Fioretti P., et al. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception 49 (1994) 33-46
17. Belsey E.M., Machin D., and d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 34 (1986) 253-260
18. Gruber D.M., Huber J.C., Melis G.B., et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 mcg and drospirenone 3 mg with a 21-day regimen of ethinylestradiol 20 mcg and desogestrel 150 mcg. Treat Endocrinol 5 (2006) 115-121
19. Mishell Jr. D.R., Guillebaud J., Westhoff C., et al. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. Contraception 75 (2007) 4-10
20. Archer D.F., Maheux R., DelConte A., et al. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). Contraception 55 (1997) 139-144
21. Archer D.F., Maheux R., DelConte A., et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 181 5 Pt 2 (1999) 39-44
22. Endrikat J., Dusterberg B., Ruebig A., et al. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 60 (1999) 269-274
23. Endrikat J., Muller U., and Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 55 (1997) 131-137
24. Schwarz B.E., Pierce C., Walden C.E., and Knopp R.H. Reference period analysis of vaginal bleeding with triphasic oral contraceptive agents containing norethindrone or levonorgestrel: a comparison study. Int J Fertil 37 (1992) 176-182